Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Heart Rhythm. 2024 Nov;21(11):2250-2259. doi: 10.1016/j.hrthm.2024.05.014. Epub 2024 May 19.
It is unknown whether cardiac resynchronization therapy (CRT) would improve or halt the progression of heart failure (HF) in patients with mild to moderately reduced ejection fraction (HFmmrEF) and left bundle branch block (LBBB).
This study aimed to investigate the outcomes of CRT in patients with HFmmrEF and left ventricular conduction delay.
A prospective, randomized clinical trial sponsored by the National Heart, Lung, and Blood Institute included 76 patients who met the study inclusion criteria (left ventricular ejection fraction [LVEF] of 36%-50% and LBBB). Patients received CRT-pacemaker and were randomized to CRT-OFF (right ventricular pacing 40 beats/min) or CRT-ON (biventricular pacing 60-150 beats/min). At a 6-month follow-up, pacing programming was changed to the opposite settings. New York Heart Association class, N-terminal pro-brain natriuretic peptide levels, and echocardiographic variables were collected at baseline, 6 months, and 12 months. The primary study end point was the left ventricular end-systolic volume (LVESV) change from baseline, and the primary randomized comparison was the comparison of 6-month to 12-month changes between randomized groups.
The mean age of the patients was 68.4 ± 9.8 years (male, 71%). Baseline characteristics were similar between the 2 randomized groups (all P > .05). In patients randomized to CRT-OFF first, then CRT-ON, LVESV was reduced from baseline only after CRT-ON (baseline, 116.1 ± 36.5 mL; CRT-ON, 87.6 ± 26.0 mL; P < .0001). The randomized analysis of LVEF showed a significantly better change from 6 to 12 months in the OFF-ON group (P = .003). LVEF was improved by CRT (baseline, 41.3% ±.7%; CRT-ON, 46.0% ± 8.0%; P = .002). In patients randomized to CRT-ON first, then CRT-OFF, LVESV was reduced after both CRT-ON and CRT-OFF (baseline, 109.8 ± 23.5 mL; CRT-ON, 91.7 ± 30.5 mL [P < .0001]; CRT-OFF, 99.3 ± 28.9 mL [P = .012]). However, the LVESV reduction effect became smaller between CRT-ON and CRT-OFF (P = .027). LVEF improved after both CRT-ON and CRT-OFF (baseline, 42.7% ± 4.3%; CRT-ON, 48.5% ± 8.6% [P < .001]; CRT-OFF, 45.9% ± 7.7% [P = .025]).
CRT for patients with HFmmrEF significantly improves LVEF and ventricular remodeling after 6 months of CRT. The study provides novel evidence that early CRT benefits patients with HFmmrEF with LBBB.
心脏再同步治疗(CRT)是否会改善或阻止射血分数轻度至中度降低(HFmmrEF)和左束支传导阻滞(LBBB)患者心力衰竭(HF)的进展尚不清楚。
本研究旨在探讨 CRT 在 HFmmrEF 和左心室传导延迟患者中的疗效。
一项由美国国立心肺血液研究所资助的前瞻性、随机临床试验纳入了符合研究纳入标准的 76 名患者(左心室射血分数 [LVEF]为 36%-50%和 LBBB)。患者接受 CRT 起搏器治疗,并随机分为 CRT-OFF(右心室起搏 40 次/分)或 CRT-ON(双心室起搏 60-150 次/分)。在 6 个月的随访时,起搏程控改变为相反的设置。在基线、6 个月和 12 个月时收集纽约心脏协会(NYHA)心功能分级、N 末端脑利钠肽前体(NT-proBNP)水平和超声心动图变量。主要研究终点是从基线到左心室收缩末期容积(LVESV)的变化,主要随机比较是两组随机变化之间的 6 个月到 12 个月的变化比较。
患者的平均年龄为 68.4 ± 9.8 岁(男性占 71%)。两组间基线特征相似(均 P >.05)。在首先接受 CRT-OFF 治疗的患者中,仅在接受 CRT-ON 治疗后 LVESV 从基线开始减少(基线时,116.1 ± 36.5 mL;CRT-ON 时,87.6 ± 26.0 mL;P <.0001)。LVEF 的随机分析显示,OFF-ON 组从 6 个月到 12 个月的变化有显著改善(P =.003)。CRT 可改善 LVEF(基线时,41.3% ±.7%;CRT-ON 时,46.0% ± 8.0%;P =.002)。在首先接受 CRT-ON 治疗的患者中,在接受 CRT-ON 和 CRT-OFF 治疗后,LVESV 均减少(基线时,109.8 ± 23.5 mL;CRT-ON 时,91.7 ± 30.5 mL [P <.0001];CRT-OFF 时,99.3 ± 28.9 mL [P =.012])。然而,CRT-ON 和 CRT-OFF 之间的 LVESV 减少效应变小(P =.027)。在接受 CRT-ON 和 CRT-OFF 治疗后,LVEF 均得到改善(基线时,42.7% ± 4.3%;CRT-ON 时,48.5% ± 8.6% [P <.001];CRT-OFF 时,45.9% ± 7.7% [P =.025])。
对于 HFmmrEF 患者,CRT 可显著改善 LVEF 和心室重构,在 CRT 治疗 6 个月后。该研究提供了新的证据,表明早期 CRT 对 HFmmrEF 合并 LBBB 患者有益。